Skip to main content
. 2014 Oct 15;7(11):7907–7914.

Figure 3.

Figure 3

Kaplan-Meier analysis for recurrence/progression-free survival according to expression of EpCAM and Trop2. A. EpCAM overexpression didn’t show prognostic value for recurrence/progression-free survival (X2EpCAM = 0.018, P = 0.892); B. Patients with Trop2 overexpression demonstrated a significantly lower recurrence/progression-free survival as compared with the cases lacking Trop2 overexpression (X2Trop2 = 4.844, P = 0.028).